Biotrial Makes Executive Appointment
Biotrial today announced the continued strengthening of its medical team with a key appointment.
Biotrial, a leading Contract Research Organization, continues to strengthen its medical team by appointing Didier Chassard (formerly with SGS) as Associate Medical and Scientific Director.
Biotrial, a leading CRO for early phase clinical trials, today announced a new executive appointment of Didier Chassard, MD, as Associate Medical and Scientific Director
Rennes, France - November 15th, 2008
Biotrial today announced the continued strengthening of its medical team with a key appointment.
Didier Chassard, MD, will be working in close collaboration with Biotrial VP of Medical and Scientific Affairs, Alain Patat, MD. Dr. Patat, who himself joined Biotrial a few years ago from Wyeth Ayerst, commented, “ I am delighted to have such a well-known and respected international pharmacologist like Dr. Didier Chassard joining our team at Biotrial Paris. His 20 years of experience in early compound development will provide a significant contribution to the services we offer in Phase I, proof-of-concept studies, and many other areas.”
Dr. Chassard comes to Biotrial from SGS Paris Clinical Unit, (formerly ASTER-CEPHAC). Over the years, Dr. Chassard has had the opportunity to develop a strong and recognized expertise in the fields of women’s health, immunology, vaccinations, and endocrinology, to name a few.
Biotrial’s recent moves to strengthen its management team show the company’s focus on fortifying its a medical and operational excellence. The appointment of Dr. Chassard follows two other recent management team addition announcements. (See related October press releases.)
“I’m very pleased that Dr. Chassard has agreed to join our management team,” said Jean-Marc Gandon, Biotrial’s CEO. “I'm confident that his strong medical background, as well as his extensive leadership experience, will be instrumental in furthering the development of our Phase I-II activities. This newest executive appointment provides the foundation for our company’s next level of growth.”
Dr. Chassard, who holds his doctorate of medicine, also has a master’s degree in Pharmacology as well as computer science, statistics and epidemiology. He will be based in the Rueil Malmaison (suburb of Paris) Biotrial Phase I unit.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
